Specific country notes have been prepared using data from the database OECD Health Statistics 2015, July 2015 version. The notes are available in PDF format.
English, PDF, 306kb
Excellent population health status and good outcomes associated with acute care reflect a high-performing health system in Norway. Norway’s good health system comes at a cost – Norway’s per capita health expenditure is the highest in Europe.
Improving primary care systems and co-ordination between health services would help Norway meet the changing needs of its healthcare system, as the population ages and hospital stays become shorter, according to a new OECD report.
This book presents a comprehensive review of health care quality in Norway. It finds that Norway has an impressive and comprehensive health system, which is the result of sustained commitment to providing health care for the whole Norwegian population, investment in the health system, and readiness to make changes to drive improvements. On most indicators Norway’s health system appears to be performing well, although there is some room for improvement. There have been a number of significant health care reforms in Norway over the last decade, most recently the Coordination Reform, which took effect in January 2012.
Broadly this is a positive story, but challenges do lie ahead for Norway. Norway is putting in place measures to respond to these challenges, notably with the 2012 Coordination Reform, but still has some way to go before the fruits of such labour are truly felt across the health system. Norway’s ambitious reform agenda must now be balanced by structured efforts ‘on the ground’. Attention should now turn to putting in place appropriate data infrastructures, promoting meaningful engagement between key stakeholders, and by balancing a generous health budget that allows for important investments in developing new structures and services with attention to getting the most out of existing services.
Norway is better placed to cope with population ageing than most other countries. But it could still do more to improve incentives and opportunities for people to stay working longer which would help ensure the country’s long-term future, according to a new OECD report.
Tackling mental ill-health of the working-age population is becoming a key issue for labour market and social policies in OECD countries. OECD governments increasingly recognise that policy has a major role to play in keeping people with mental ill-health in employment or bringing those outside of the labour market back to it, and in preventing mental illness. This report on Norway is the fourth in a series of reports looking at how the broader education, health, social and labour market policy challenges identified in Sick on the Job? Myths and Realities about Mental Health and Work (OECD, 2012) are being tackled in a number of OECD countries. It concludes that Norway faces a unique situation whereby a generous welfare system stimulates large-scale labour market exclusion and significant socio-economic inequalities of people with a mental disorder, and hindering better outcomes of its employment and vocational rehabilitation programmes.
To assess the feasibility of using secondary data sets information to feed an output-based PPP approach for hospital services, we reviewed the main characteristics of diagnoses and procedures coding standards, DRG classification systems, and cost-finding methods used in selected OECD countries.
The mortality amenable to health care is defined as a possible indicator to measure the health care systems performance in preventing premature deaths that can be avoided by appropriate health care intervention. This paper assesses the feasibility of using this indicator in OECD countries.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.